lutikizumab   Click here for help

GtoPdb Ligand ID: 9297

Synonyms: ABT-981 | E26.13-SS-X3 [6]
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lutikizumab (ABT-981) is an investigational monoclonal antibody targeting IL-1α and IL-1β [6], designed using proprietary technology to create dual variable domain antibodies ('DVD-IgTM') [3]. DVD-Igs are single pharmaceutical agents capable of simultaneously targeting two mediators of disease. The unique feature of DVD-Igs is that each arm of the antibody contains two tandem variable domains, each capable of binding a different antigen (see Figure 2 in [6]).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
No information available.
Summary of Clinical Use Click here for help
ABT-981 has reached Phase 2a clinical trial in patients with OA of the knee (NCT02087904) and hand (NCT02384538). Phase 1 satety and tolerability findings from NCT01668511 are published in [8].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IL-1 stimulates degradation of cartilage [1-2,7] and inhibits damage repair in osteoarthritis (OA) [4-5]. Agents which neutralise the activity of IL-1 would therefore be expected to ameliorate the effects of excessive IL-1 activity in OA patients. Antibodies offer the advantage of extended duration of action over smaller peptides like the IL-1 receptor antagonist, anakinra.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01668511 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee Phase 1 Interventional AbbVie
NCT02087904 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis Phase 2 Interventional AbbVie
NCT02384538 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis Phase 2 Interventional AbbVie